Abstract：
OBJECTIVE: Status epilepticus (SE) is defined by abnormally prolonged seizures that may lead to brain damage and death. Our aim was to evaluate the efficacy and tolerability (effectiveness) of intravenous brivaracetam (BRV) as a second-line treatment.
METHODS: Twenty-one patients (median age 68 years ± 17.28) were prospectively recruited between June 2019 and December 2022. Patients were treated with BRV (50-200 mg) as a second-line add-on therapy for SE. We evaluated the response of SE to the administration of BRV in terms of SE termination and recurrence of epileptic seizures at 6, 12, and 24 h, also monitoring safety. The first-line therapy was represented by intravenous benzodiazepines (mainly diazepam).
RESULTS: Almost a quarter of patients had generalized seizures, whereas the vast majority (76.2%) presented focal seizures. In 52.4% of patients, the underlying cause was cerebrovascular. Fourteen (66.7%) patients displayed a good early response in the subsequent 6 h. At 12 and 24 h, 8 (38%) and 11 (52.4%) patients, respectively, did not present seizures.
CONCLUSIONS: The present study highlights the potential of BRV when used as an early add-on therapy in SE, further confirming its good safety profile.
METHODS: Twenty-one patients (median age 68 years ± 17.28) were prospectively recruited between June 2019 and December 2022. Patients were treated with BRV (50-200 mg) as a second-line add-on therapy for SE. We evaluated the response of SE to the administration of BRV in terms of SE termination and recurrence of epileptic seizures at 6, 12, and 24 h, also monitoring safety. The first-line therapy was represented by intravenous benzodiazepines (mainly diazepam).
RESULTS: Almost a quarter of patients had generalized seizures, whereas the vast majority (76.2%) presented focal seizures. In 52.4% of patients, the underlying cause was cerebrovascular. Fourteen (66.7%) patients displayed a good early response in the subsequent 6 h. At 12 and 24 h, 8 (38%) and 11 (52.4%) patients, respectively, did not present seizures.
CONCLUSIONS: The present study highlights the potential of BRV when used as an early add-on therapy in SE, further confirming its good safety profile.
摘要：
目的：癫痫持续状态（SE）定义为异常长时间的癫痫发作，可能导致脑损伤和死亡。我们的目的是评估静脉注射布立西坦（BRV）作为二线治疗的疗效和耐受性（有效性）。
方法：在2019年6月至2022年12月期间，前瞻性招募了21名患者（中位年龄68岁±17.28）。患者接受BRV（50-200mg）作为SE的二线附加疗法。我们在6、12和24小时评估了SE终止和癫痫发作复发方面对BRV给药的反应，还监测安全。一线治疗以静脉注射苯二氮卓类药物（主要是地西泮）为代表。
结果：几乎四分之一的患者有全身性癫痫发作，而绝大多数(76.2%)出现局灶性癫痫发作.在52.4%的患者中，根本原因是脑血管。14例（66.7％）患者在随后的6小时内表现出良好的早期反应。在12和24小时，8例（38%）和11例（52.4%）患者，分别,没有出现癫痫发作。
结论：本研究强调了BRV作为SE的早期附加疗法的潜力，进一步确认其良好的安全性。
方法：在2019年6月至2022年12月期间，前瞻性招募了21名患者（中位年龄68岁±17.28）。患者接受BRV（50-200mg）作为SE的二线附加疗法。我们在6、12和24小时评估了SE终止和癫痫发作复发方面对BRV给药的反应，还监测安全。一线治疗以静脉注射苯二氮卓类药物（主要是地西泮）为代表。
结果：几乎四分之一的患者有全身性癫痫发作，而绝大多数(76.2%)出现局灶性癫痫发作.在52.4%的患者中，根本原因是脑血管。14例（66.7％）患者在随后的6小时内表现出良好的早期反应。在12和24小时，8例（38%）和11例（52.4%）患者，分别,没有出现癫痫发作。
结论：本研究强调了BRV作为SE的早期附加疗法的潜力，进一步确认其良好的安全性。
